Delivra Health Brands CEO Gord Davey joined Steve Darling from to discuss the launch of LivRelief Itch Cream, a new product designed to help relieve itchiness associated with eczema, psoriasis, dermatitis, and other common skin irritations. Davey said the cream is formulated for sensitive skin and is hypoallergenic, fragrance-free, and free from parabens, petroleum, and SLS. The product combines Hydrocortisone, Calendula, and Chamomile to help reduce itching, irritation, and inflammation. In addition to eczema and psoriasis-related discomfort, LivRelief Itch Cream can also be used for the temporary relief of minor skin irritations such as rashes, redness, insect bites, poison ivy, poison oak, and poison sumac. Management says the launch targets a large and underserved market. According to the Canadian Dermatology Association, up to 17% of Canadians will experience atopic dermatitis at some point in their lives. Davey also pointed to the Eczema Society of Canada’s 2025 survey, which found that 89% of respondents identified itch reduction as a key treatment goal, while 86% wanted better control of rash and skin symptoms. In addition, Psoriasis Canada estimates that more than one million Canadians are affected by psoriasis and psoriatic arthritis. Delivra believes the new LivRelief Itch Cream expands its topical wellness and pain-relief portfolio while addressing a clear consumer need for effective, accessible, and skin-friendly itch relief solutions. #proactiveinveestors #delivrahealthbrandsinc #tsxv #dhb #otcqb #dhbuf #DreamWater #GlobalExpansion #DreamWater #LivRelief #CBD #Cannabis #Wellness #Topicals #Canada #ConsumerGoods #LivRelief #Healthcare #CannaTech